11-Jun-2021 | Facts and Factors
According to a recent market research analysis published by Facts & Factors, the global antithrombin market was about USD 678.56 Million in 2020, with sales estimated to reach about USD 752.2 Million by the end of 2026 and an excellent 5.6% CAGR from 2021 to 2026.
Antithrombin is a protein-bound composite in the human body that acts as a blood thinner. It is used extensively in surgical procedures to mimic the condition that it renders in order to provide any harmful effects to the patient. The driving forces behind the growth of the antithrombin market are the rise in disorders related to the latter such as sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (EMCO).
Moreover, a rise in open-heart surgeries has opened opportunities for the growth of the antithrombin market to expand during the forecast. A trend of people suffering from antithrombin deficiency is on the rise which makes the antithrombin drugs supplementary a reliable source. Increased functionality of the drug further makes it extremely viable to be integrated in the final stages of any clinical trial that intends to plaster blood clotting disorders.
Top Market Players
The key participants in the global antithrombin market are Grifols SA., Octapharma AG, LFB, CSL Limited, Takeda Pharmaceutical Company Limited, Keridon S.p.A., Lee Biosolutions, Scripps Laboratories, Inc., GTC Biotherapeutics, Inc., and BDI Pharma, among others.
Market Dynamics
Here are some noteworthy mentions in the global antithrombin market during the forecast –
- The Food and Drug Administration approved an Rx known as ATryn – A genetically modified compound from goats that can produce blood-thinning protein antithrombin.
- GTC Biotherapeutics, Inc., announced a change in brand name in order to renew their consumers’ faith towards evolving recombinant medicine.
- CSL Limited recently acquired a higher stake in a China-based plasma fractionator in order to open a new revenue pathway and tap a previously untapped market.
- Octapharma recently launched Nuwiq that can be used to treating patients from perioperative management and routine prophylaxis for adults and children suffering from hemophilia A.
The global antithrombin market can be segmented into human, goat milk, and others on the basis of the source. The segment of goat milk will contribute the largest in terms of global revenue collection. Factors pertaining to the growth of the market during the forecast can be credited to the low cost of the product coupled with easy availability and proven clinical efficacy.
The global antithrombin market can be fragmented into therapeutics, diagnostics, research, and others on the basis of application. The therapeutics segment is expected to witness the largest market share during the forecast owing to governing factors such as the rising prevalence of antithrombin deficiencies and increasing cases of blood disorders.
Asia-Pacific Is Projected To Occupy The Largest Market Share During the Forecast Period
Asia-Pacific is expected to witness the largest market share during the factor in terms of global revenue contribution. Factors responsible for the dominant position in the market can be credited to the emerging economies in the region – China & India. Furthermore, the prevalence of venous thromboembolism (VTE) in the Asian population is expected to occur at a much lower rate than the western counterparts. Growing patient awareness and increased consumer spending on healthcare facilities will further boost the growth of the market during the forecast timeframe.
Browse the full “Antithrombin Market By Source (Human, Goat Milk, & Others), By Application (Therapeutics, Diagnostics, Research, & Others), By Dosage Form (Lyophilized & Liquid), By Route (Oral & Parental), And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 - 2026” report at https://www.fnfresearch.com/antithrombin-market
Report Scope
Report Attribute |
Details |
Market Size in 2020 |
USD 678.56 Million |
Projected Market Size in 2026 |
USD 752.2 Million |
CAGR Growth Rate |
5.6% CAGR |
Base Year 2020 |
Forecast Years |
2021-2026 |
Key Market Players |
Grifols SA., Octapharma AG, LFB, CSL Limited, Takeda Pharmaceutical Company Limited, Keridon S.p.A., Lee Biosolutions, Scripps Laboratories, Inc., GTC Biotherapeutics, Inc., and BDI Pharma, among others. |
Key Segment |
By Source, By Application, By Dosage Form, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
The global antithrombin market can be segmented into:
Global Antithrombin Market: By Source Segment Analysis
Global Antithrombin Market: By Application Segment Analysis
- Therapeutics
- Diagnostics
- Research
- Others
Global Antithrombin Market: By Dosage Form Segment Analysis
Global Antithrombin Market: By Route Segment Analysis
Global Antithrombin Market: By Regional Segment Analysis
- North America
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
